Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2009

View Archived Issues

Phase II data presented for enzastaurin as add-on therapy to pemetrexed/cisplatin in NSCLC

Data reported for antibacterials TR-700 and TR-701

AFN-1252 pharmacokinetic data from phase 0 and phase I studies analyzed

Phase I/II and ex vivo data show IPH-1101 to be beneficial

DSP-8658 shows favorable antidiabetic activity in mouse models of obesity and diabetes

LY-2189265 does not affect serum lipase and amylase levels in type 2 diabetes

PAION completes phase Ib trial of anesthetic/sedative CNS-7056 in colonoscopy

YM BioSciences to acquire all issued Cytopia shares and options

FDA advisory committee recommends approval of Pegintron in malignant melanoma

Boston Scientific enters into exclusive sponsorship agreement for MADIT-RIT clinical trial

FDA accepts for review ProStrakan's NDA for Abstral for breakthrough pain in cancer

Cimzia/MTX combination is approved in Europe for rheumatoid arthritis

PDS Biotechnology reports toxicology results for Versamune-based HPVcancer product

Depomed presents topline results from phase III trial of DM-1796

Acadia presents update on phase III program of pimavanserin in PD psychosis

Immutep reports interim phase I/II trial results for IMP-321 in metastatic breast cancer

Idera initiates phase I trial evaluating IMO-2125 in combination with ribavirin

TiGenix obtains European approval for ChondroCelect for knee cartilage regeneration

Novel iron chelators described by BTG

CRTH2 antagonists for the treatment of asthma presented by Abbott

Synta Pharmaceuticals discloses Hsp70 inducers for the treatment of cancer

European Commission approves Centocor's Simponi in RA, PsA and AS

FDA issues complete response letter regarding Genzyme's sNDA for Clolar in AML

FDA grants OncoGenex additional fast track designation for OGX-011

Repros Therapeutics reports results from Androxal study in secondary hypogonadism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....